Premium
Diabetes‐mediated myelopoiesis and the relationship to cardiovascular risk
Author(s) -
Barrett Tessa J.,
Murphy Andrew J.,
Goldberg Ira J.,
Fisher Edward A.
Publication year - 2017
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/nyas.13462
Subject(s) - myelopoiesis , medicine , diabetes mellitus , type 2 diabetes , disease , risk factor , pathophysiology , inflammasome , immunology , inflammation , haematopoiesis , endocrinology , biology , stem cell , microbiology and biotechnology
Diabetes is the greatest risk factor for the development of cardiovascular disease, which, in turn, is the most prevalent cause of mortality and morbidity in diabetics. These patients have elevations in inflammatory monocytes, a factor consistently reported to drive the development of atherosclerosis. In preclinical models of both type 1 and type 2 diabetes, studies have demonstrated that the increased production and activation of monocytes is driven by enhanced myelopoiesis, promoted by factors, including hyperglycemia, impaired cholesterol efflux, and inflammasome activation, that affect the proliferation of bone marrow precursor cells. This suggests that continued mechanistic investigations of the enhanced myelopoiesis and the generation of inflammatory monocytes are timely, from the dual perspectives of understanding more deeply the underlying bases of diabetes pathophysiology and identifying therapeutic targets to reduce cardiovascular risk in these patients.